The global market for neutropenia treatment is projected to experience a notable growth, climbing up from an evaluation of US$ 16.2 Billion in 2024 to an expected level of US$ 25.9 Billion by 2034. This discernable upward trend is largely propelled by the rising incidence of cancer cases across the globe. Cancer patients, particularly those undergoing rigorous therapy regimes, often experience a weakened immune system, leading to neutropenia.
Moreover, the rising employment of chemotherapy treatments further underpins the infuriating need for potent treatments aiming to manage or avert neutropenia amid cancer care. The escalating requirement is mirrored through World Health Organization’s (WHO) recent data, stating nearly 20 million fresh cancer cases and 9.7 million deaths due to cancer worldwide in 2022. As cancer sufferers frequently necessitate intensive care therapy, healthcare systems worldwide are levelling up their action plan concerning auxiliary care wherein neutropenia management is considered critical.
Neutropenia management helps keep patients’ immunity intact, shielding them against infections triggering complexities or treatment delays. The evolution of biologic therapies and granulocyte colony-stimulating factors (G-CSFs), devised to enhance bone marrow’s neutrophil production, has revolutionarily upskilled the neutropenia treatment sphere.
Another striking trend in the market is customizing treatments based on personal factors, paving the way for better results and reducing unwanted side effects. Apart from this, long-acting injectable therapies, which minimize hospital visit frequencies for patients, are gaining popularity, enhancing patient convenience and overall quality of life. With advanced comprehension, the neutropenia treatment market is gradually making a shift toward more targeted therapies. Healthcare providers and pharmaceutical companies are making substantial investments in the field with the aim to meet the growing treatment demand.
As advancements continue to see the light of the day, the neutropenia treatment market is anticipated to witness enduring growth in the coming years. North America is expected to continue leading the neutropenia treatment market, attributed to the high incidence of cancer in the region and frequent usage of myelosuppressive chemotherapy treatments that often reduce white blood cell counts, leading to neutropenia.
Nonetheless, the market’s potential growth is further amplified by the escalating usage of granulocyte colony-stimulating factors (G-CSFs) and biosimilars that aid in managing low neutrophil counts and decrease infection risk. Colony-stimulating factors (CSFs) are expected to command the neutropenia treatment market with a 51.8% share. Hospital pharmacies are projected to hold a substantial 57.6% of the market share. In the wake of newer therapeutic inventions and increased awareness, the future of neutropenia care appears promising across various patient groups.
Source: https://media.market.us/neutropenia-treatment-market-news/